News

Longeveron Welcomes Than Powell as Chief Business Officer

Longeveron Welcomes Than Powell as Chief Business Officer

Significant Leadership Change at Longeveron

MIAMI — In a strategic move, Longeveron Inc. (NASDAQ: LGVN), a biotechnology firm focused on regenerative medicine, has appointed Than Powell as its new Chief Business Officer. This announcement marks a pivotal moment in Longeveron’s journey as they pioneer innovative therapies for serious conditions associated with aging and other chronic diseases.

A Leader in Business Strategy

Effective July 7, 2025, Than Powell will be at the forefront of Longeveron’s business strategy, specifically focusing on navigating the complex landscape of partnerships, particularly regarding Alzheimer's disease. Additionally, he will steer the international strategy for the hypoplastic left heart syndrome (HLHS) program, showcasing his extensive background in the pharmaceutical and biotechnology sectors.

Transformative Period for the Company

“We are thrilled to welcome Than aboard during this transformative phase for Longeveron,” expressed Wa’el Hashad, the CEO of the company. With the recent milestone of enrolling participants in a pivotal Phase 2 trial assessing laromestorcel, a stem cell therapy for HLHS, Longeveron is on the brink of reviewing pivotal data. This positive outcome may lead the way for the firm's first Biological License Application (BLA) submission, a significant achievement in the biopharmaceutical arena.

Than Powell’s Impressive Background

Than Powell brings over 25 years of invaluable experience to Longeveron, having held various leadership roles in established pharmaceutical firms, including GSK and Eli Lilly. His previous position as head of Corporate Development & Strategy at Surescripts culminated in the company's acquisition by TPG, highlighting his knack for driving corporate growth.

Commitment to Longeveron’s Mission

“I am honored to join Longeveron,” Powell remarked about his new position. “The innovative spirit and commitment to scientific excellence at Longeveron resonate with me, especially given my family's personal experiences with diseases currently under study. I look forward to advancing the company's mission and aiding patients through potential stem cell therapy approvals.”

About Longeveron Inc.

Longeveron stands at the cutting edge of regenerative medicine, dedicated to developing groundbreaking therapies to address unmet medical needs. Their flagship investigational product, laromestrocel (Lomecel-B™), is designed to leverage the regenerative capabilities of stem cells derived from the bone marrow of healthy, young donors. This innovative therapy holds promise across various disease areas due to its multiple mechanisms, including pro-vascular and anti-inflammatory effects.

Significant FDA Designations

Currently, Longeveron is engaged in three crucial pipeline indications, namely HLHS, Alzheimer’s disease, and Aging-related Frailty. With recognition from the FDA, laromestrocel has received notable designations like Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation for HLHS. Furthermore, its Alzheimer’s program also benefits from the Regenerative Medicine Advanced Therapy (RMAT) designation, supporting its expedited development.

Contact Information

For further inquiries, interested parties can reach out to Derek Cole at Investor Relations Advisory Solutions via email at derek.cole@iradvisory.com. Longeveron invites those eager to learn more about their innovative endeavors to visit their official website and stay updated through their social media channels.

Frequently Asked Questions

What role will Than Powell serve at Longeveron?

Than Powell will function as the Chief Business Officer, overseeing the company's business strategy and global initiatives.

What is laromestrocel?

Laromestrocel (Lomecel-B™) is a stem cell therapy aimed at addressing various health conditions, especially those related to aging and chronic diseases.

What sectors will Longeveron focus on with Powell's leadership?

Under Powell’s guidance, Longeveron will enhance its efforts in Alzheimer's disease and develop international strategies for its HLHS program.

How long has Than Powell been in the pharmaceutical industry?

Than Powell has over 25 years of experience across various significant organizations in the pharmaceutical and biotech sectors.

What are the FDA designations Longeveron has received?

Longeveron’s laromestrocel has garnered multiple FDA designations, including Orphan Drug, Fast Track, and Rare Pediatric Disease for HLHS.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

California Stone Ban Puts a Hidden Worker Toll in View

Updated Category News Views 5

Countertops are supposed to finish a kitchen, not quietly wreck the lungs of the people cutting them. Yet California's move toward prohibiting the fabrication and installation of artificial stone containing more than 1% crystalline silica puts an ugly, long-running occupational-health problem in plain sight. This is not a story that calls for chest-thumping market talk....

Continue Reading
Pennsylvania Housing Finds Its October Holding Pattern

Updated Category News Views 79

Pennsylvania's October housing numbers have the uneasy stillness of a pond before somebody throws a rock. The statewide median sales price sat at $315,000, exactly where it was in September, while sales barely cleared 10,400 and available listings kept inching higher. Nothing in that mix screams boom or bust. Frankly, that is the point: a market can look calm on the...

Continue Reading
D-Wave Investors Face December 15 Lead Plaintiff Clock

Updated Category News Views 83

Quantum dreams met a very earthly spreadsheet problem at D-Wave this summer. The proposed securities class action against D-Wave Quantum Inc. puts a hard date on the issue for investors who bought shares between February 26 and August 25, 2026: December 15, 2026 is the deadline to seek lead-plaintiff status. That does not mean every holder needs to march into court. It...

Continue Reading
Dario's Personify Panel Puts Distribution Model in Focus

Updated Category News Views 229

A Partner Megaphone Is Not a Revenue Line Monday's virtual panel gives DarioHealth a useful stage, but investors should not confuse a conference microphone with a signed sales order. Erez Raphael is set to lead a November 23 discussion with Personify Health President Ed Liebowitz at the U.S. Bancorp | BTIG Tech-Enabled Healthcare Forum, running from noon to 12:50 p.m....

Continue Reading
HVAC’s $383.6 Billion Shift Is About More Than Units

Updated Category News Views 163

Server racks are turning cooling gear into a front-row industrial story, and that deserves more attention than the usual sleepy talk about replacement air conditioners. Frost & Sullivan projects the global HVAC equipment market will reach $383.6 billion by 2031, growing at a 7.0% compound annual rate from 2025. That is a sizable market, sure, but the more interesting...

Continue Reading
Wenge AI Removes a Small Friction Point for ScienceOra

Updated Category News Views 84

Scientific software rarely loses users because the underlying model is too clever; it loses them because getting through the front door is a nuisance. Wenge AI has addressed that unglamorous problem by adding Google and Apple sign-in options to the international version of ScienceOra, its AI-powered research and decision-support platform. This is not the sort of...

Continue Reading
Pepsi Faces Georgia Labor Pressure Ahead of Strike

Updated Category News Views 5

A Pre-Dawn Labor Test Is Brewing in Georgia At 2:30 in the morning, nobody gathers outside a distribution center for the scenery. More than 100 Pepsi-Cola drivers from Atlanta and Lithonia are slated to meet Tuesday, November 24, at the Pepsi Distribution Center in Lithonia, Georgia, with Teamsters General President Sean M. O'Brien joining them. That hour matters. It puts...

Continue Reading
Cloud Security’s $26.8 Billion Test Is All About Execution

Updated Category News Views 59

A cloud dashboard that spits out ten thousand alerts is not protection; it is an expensive way to make a security team miserable. That frustration sits right in the middle of Frost & Sullivan’s projection that global cloud security revenue will climb from $8.4 billion in 2025 to $26.8 billion by 2031, a 21.4% compound annual growth rate. The number is hefty, no...

Continue Reading
AI Governance Is Becoming Enterprise Infrastructure

Updated Category News Views 43

Governance Has Finally Reached the Engine Room Enterprise AI is no longer a shiny pilot parked in some innovation lab; it is creeping into business-critical work, and that changes the argument entirely. Frost & Sullivan’s latest analysis makes a sensible point that too many executives still resist: AI governance is becoming a strategic operating capability, not merely a...

Continue Reading
Healthcare's Prevention Puzzle Needs Better Incentives

Updated Category News Views 60

When Savings Belong to the Next Plan A patient changing insurance plans can turn prevention into nobody’s asset. That is the uncomfortable little engine inside Russell Greenfield’s recent argument: an insurer may pay today for a program that helps prevent chronic illness, only to watch the eventual savings land with another plan after the member moves on. The person...

Continue Reading

Top 5 Most Recently Viewed Articles

Indovinya Unveils Challenge for Innovative Fragrance Solutions

Updated Category News Views 148

Indovinya Launches Open Innovation Challenge Researchers and startups with a focus on developing sustainable solutions for fragrance solubilization are invited to apply for an exciting new challenge initiated by Indovinya, the specialty chemicals and surfactants division of Indorama Ventures. The aim is to enhance fragrance solubilization without the use of ethoxylates,...

Continue Reading
Capricor Therapeutics to Highlight Innovations at Investor Events

Updated Category News Views 156

Capricor Therapeutics to Highlight Innovations at Investor Events Capricor Therapeutics (NASDAQ: CAPR), a leading biotechnology company based in San Diego, is committed to developing transformative cell and exosome-based therapies aimed at addressing rare diseases. Recently, the company announced a series of presentations scheduled at prominent investor conferences, where...

Continue Reading
Trump Media Takes Bold Step Into Financial Sector with New ETFs

Updated Category News Views 179

Trump Media's Financial Leap Trump Media & Technology Group Corp. (NASDAQ: DJT) is embarking on an exciting journey into the financial landscape. The company's fintech and streaming divisions are rolling out an innovative suite of five new exchange-traded funds (ETFs). These funds are crafted around the compelling themes of 'America First', aiming to appeal to socially...

Continue Reading
Vascular Access Device Market Set to Hit $8.68 Billion Milestone

Updated Category News Views 133

Overview of the Vascular Access Device Market The vascular access device market is on a promising trajectory, projected to escalate from around USD 6.27 billion to USD 8.68 billion by 2031, reflecting a compound annual growth rate (CAGR) of 6.7%. This significant growth is positioned to enhance patient care in various healthcare settings, emphasizing the vital role of...

Continue Reading
Oscar Health: Navigating the Storm in Health Insurance Market

Updated Category News Views 269

Oscar Health: Understanding the Current Landscape The US health insurance sector is facing unprecedented challenges this year. With a significant number of individuals at risk of losing health insurance coverage due to substantial budget cuts, many are seeking medical care while they still can. This surge in demand has resulted in soaring utilization rates, pushing...

Continue Reading